Pharmacokinetics of BF2.649 in Renal Impairment

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bioprojet
ClinicalTrials.gov Identifier:
NCT01619033
First received: July 20, 2011
Last updated: April 11, 2013
Last verified: April 2013

July 20, 2011
April 11, 2013
July 2011
November 2012   (final data collection date for primary outcome measure)
Mesure of classic pharmacokinetic parameters determined on BF2.649 serum and urine concentration [ Time Frame: between H0(0hr - Pre-dose) and H96 (96hr) after single oral dose ] [ Designated as safety issue: Yes ]
Cmax, Tmax, AUClast, AUC∞, λz, t½term, CL/F, Vz/F
Same as current
Complete list of historical versions of study NCT01619033 on ClinicalTrials.gov Archive Site
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: during the 4 days following the drug administration ] [ Designated as safety issue: Yes ]
    clinical safety of BF2.649.
  • change in lab tests (biological and clinical safety) [ Time Frame: during 4 days after drug administration ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Pharmacokinetics of BF2.649 in Renal Impairment
Pharmacokinetics of 20 mg BF2.649 in Single Dose, in Subjects With Normal Renal Function Compared to Subject With Impaired Renal Function

This is an open, parallel group study in subjects with normal renal function compared to those with renal dysfunction.

The pharmacokinetic of BF2.649 (pitolisant) is already well established from several studies in healthy human, and a recent pharmacokinetic study gave data on 12 young healthy volunteers compared to 12 elderly subject receiving 20mg/day during 14 days.

The aim of this study is to investigate effect of renal impairment on the pharmacokinetics of BF2.649 administrated on a single oral dose of 20 mg.

The once daily dose of 20 mg BF2.649 (pitolisant) chosen for this study corresponds to the usual therapeutic dose.

Twenty four subjects will be stratified according to renal function by using assessment of glomerular filtration rate (GFR) as defined by MDRD formula as follows:

  • 4 subjects from 18 to 75 years of age with mild impaired renal function defined by GFR between 60 and 89 ml/min (STAGE 2 according to the international classification of chronic kidney disease)
  • 4 subjects from 18 to 75 years of age with moderate impaired renal function defined by GFR between 30 and 59 ml/min (STAGE 3 according to the international classification of chronic kidney disease)
  • 4 subjects from 18 to 75 years of age with severe impaired renal function defined by GFR between 15 and 29 ml/min (STAGE 4 according to the international classification of chronic kidney disease)
  • 12 healthy subjects with normal renal function defined by GFR>90 ml/min with no proteinuria (<0.15g/L determined by urinalysis) matched with impaired renal function subjects on ethnic group, sex, age (+/- 5 years), and BMI (+/- 20%)
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Renal Impairment
Drug: BF2.649
single dose 20 mg
Other Name: Pitolisant
  • Experimental: impaired renal function subjects
    impaired renal function subjects
    Intervention: Drug: BF2.649
  • Healthy volunteers
    matched with impaired renal function subjects on ethnic group, sex, age (+/- 5 years), and BMI (+/- 20%)
    Intervention: Drug: BF2.649
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

For subjects with impaired renal function:

  • Subjects 18 to 75 years old with impaired renal function (MDRD formula between 15 and 89mL/min) medically stable since 3 months
  • With body mass index (weight/height2) in the range 18 to 32 kg/m2 (inclusive)

For healthy subjects:

  • Healthy subjects 18 to 75 years old with normal renal function (MDRD > 90 mL/min) and no proteinuria (<0.15g/L determined by urinalysis) matched with impaired renal function subjects on ethnic group, sex, age (+/- 5 years), and BMI (+/- 20%)

Exclusion Criteria:

For impaired renal function subjects:

  • History of hepatic, cardiovascular (including conduction disturbance) or psychiatric disorder or any other condition which, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of study results.
  • Evidence of liver disease
  • Presence of concomitant pathology requiring intake of any drugs or substances known to be inhibitors or inductors of CYP enzymes
  • Presence of metabolic or ionic disorders not controlled by adapted treatment
  • Presence of significant anemia,nephrotic syndrome
  • Renal transplantation

For healthy subjects:

  • history of renal, cardiovascular, gastrointestinal, hepatic, neurological, endocrine or psychiatric disorders or any surgery which puts them at risk in the opinion of the investigator.
  • Any treatment within 14 days before inclusion, or within 5 times the elimination half-life of that drug, whichever the longest, including treatment which could lead to inhibition or induction of CYP enzymes - mainly CYP3A4 and CYP2D6 and with the exception of hormonal contraception and menopausal hormone replacement therapy
Both
18 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01619033
P09-13 / BF2.649, 2011-001430-42
No
Bioprojet
Bioprojet
Not Provided
Principal Investigator: Claire POUTEIL-NOBLE, MD Nephrologie, Centre Hospitalier Lyon Sud
Bioprojet
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP